Several previous studies have reported that silencing NRF2 sensitizes tumor cells to GPX4 inhibitors in head and neck cancer as well as acute myeloid leukemia [33, 34], indicating that NRF2 renders tumor cells resistant to ferroptosis. Here, NFE2L2 is linked to head and neck cancer.